Tag Archive for: immunooncology

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

/in

Financing led by Investissement Québec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients Montreal, Canada – Strasbourg, France – Boston, United States, February 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced […]

Read more

Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine

/in

Financing co-led by Octopus Ventures and new investor Amplify Bio Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer Oxford, UK – 21 January 2026 – Infinitopes, a clinical-stage cancer vaccine biotechnology company, today announced the successful completion of the second close of its seed […]

Read more

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

/in

Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco epitope, and U5snRNP200, an ectopically expressed antigen highly specific for AML blast. Lead program KBA1412 is advancing […]

Read more

Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published

/in

Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract for a poster presentation at the ESMO Congress 2023 today has been published online on the ESMO website. After the submission of the abstract, the data set to be included in […]

Read more

IO Biotech Appoints Heidi Hunter to its Board of Directors

/in

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter, an accomplished global biotech leader with over 25 years of experience across the pharmaceutical value chain, […]

Read more
© Optimum Strategic Communications.